BG108784A - Medicamentous form of propaphenone and process for the preparation thereof - Google Patents

Medicamentous form of propaphenone and process for the preparation thereof

Info

Publication number
BG108784A
BG108784A BG108784A BG10878404A BG108784A BG 108784 A BG108784 A BG 108784A BG 108784 A BG108784 A BG 108784A BG 10878404 A BG10878404 A BG 10878404A BG 108784 A BG108784 A BG 108784A
Authority
BG
Bulgaria
Prior art keywords
preparation
propaphenon
hydrochloride
sodium glycolate
medicamentous form
Prior art date
Application number
BG108784A
Other languages
Bulgarian (bg)
Other versions
BG65678B1 (en
Inventor
Ангел ТИМЧЕВ
Виолета ПАВЛОВА
Радка ГРОЗДЕВА
Веселин ДАСКАЛОВ
Янка БОРИСОВА
Веселин БАНГИЕВ
Антоанета ПАПАГАЛСКА
Original Assignee
"Софарма" Ад
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Софарма" Ад filed Critical "Софарма" Ад
Priority to BG108784A priority Critical patent/BG65678B1/en
Publication of BG108784A publication Critical patent/BG108784A/en
Publication of BG65678B1 publication Critical patent/BG65678B1/en

Links

Abstract

The invention relates to an orally administered medicamentous form containing 1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)-propoxy]phenyl]-3-phenyl-, hydrochloride known as propaphenon hydrochloride which is administered as anti-arrhythmic means in symptomatic and tachycardiac rhythm heart trouble and to a method for its preparation. The composition of the medicamentous form and the process for its preparation ensure the formation of tablet cores having excellent physicomechanical characteristics and degree of the propaphenon dissolution. The medicamentous form comprises propaphenon hydrochloride from 150 to 300 mg, two binders, copovidon from 5 to 10 wt.% and sodium glycolate starch from 2 to 6 wt.%, respectively of the mass of the tablet core, and fillers: microcrystalline cellulose, wheat starch and magnesium stearate. The process for its preparation includes the dry binding of the active substance with particle size distribution: 90% of sizes smaller than 35 micro m, 50% sizes smaller than 20 micro m with copovidon and subsequent formation of granulate mass by means of a granulation agent - aqueous gum of sodium glycolate starch, preferably sodium glycolate starch type A with viscosity higher than 40 mPa.s.
BG108784A 2004-07-02 2004-07-02 Drug formulation of propafenone and method of obtaining it BG65678B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG108784A BG65678B1 (en) 2004-07-02 2004-07-02 Drug formulation of propafenone and method of obtaining it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG108784A BG65678B1 (en) 2004-07-02 2004-07-02 Drug formulation of propafenone and method of obtaining it

Publications (2)

Publication Number Publication Date
BG108784A true BG108784A (en) 2006-02-28
BG65678B1 BG65678B1 (en) 2009-06-30

Family

ID=36999750

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108784A BG65678B1 (en) 2004-07-02 2004-07-02 Drug formulation of propafenone and method of obtaining it

Country Status (1)

Country Link
BG (1) BG65678B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043950A3 (en) * 2008-10-15 2010-12-02 Aizant Drug Research Solutions Private Limited Propafenone extended release composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043950A3 (en) * 2008-10-15 2010-12-02 Aizant Drug Research Solutions Private Limited Propafenone extended release composition

Also Published As

Publication number Publication date
BG65678B1 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
JP5183470B2 (en) Pharmaceutical composition containing levetiracetam and method for its preparation
HRP20200753T1 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
CA2722093C (en) Pharmaceutical compositions comprising brivaracetam
CA2470601A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JP2007518760A5 (en)
JP2019505525A (en) Pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof
RU2007137434A (en) TABLETED MEDICINE WITH SLOW-RELEASED REMOVAL FOR VERTIGO
JP2014024874A (en) Compressed preparation
EP1994926B9 (en) Valsartan formulations
RU2002123182A (en) CONTAINING IBUPROFEN COMPOSITION
WO2012136839A1 (en) Dry formulation and pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
CN102846573B (en) Silibinin double-layer slow-release tablets and preparation method thereof
JP5575114B2 (en) Granules containing escitalopram oxalate
CN101332193B (en) Preparation method of fluvoxamine maleate medicine composition
BG108784A (en) Medicamentous form of propaphenone and process for the preparation thereof
EP1517683B1 (en) Sustained release tablet containing indapamide
RU2463039C2 (en) Escitalopram and hard pharmacetical composition containing it
CZ301299B6 (en) Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients
RU2251420C2 (en) Ciprofloxacin-containing pharmaceutical composition and method for its obtaining
JPWO2004006945A1 (en) Kampo extract-containing tablet composition and method for producing the same
CN106692149A (en) Cariprazine medical oral preparation and preparation method thereof
CN104000821B (en) Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof
CN101103967B (en) Medicine composition containing bevantolol hydrochloride
CA2531486A1 (en) Saquinavir mesylate oral dosage form